Inventiva Introduces Design for its Phase III Nonalcoholic Steatohepatitis Trial
source: pixabay.com

Inventiva Introduces Design for its Phase III Nonalcoholic Steatohepatitis Trial

According to a story from dernieresactus.fr, the biopharmaceutical company Inventiva has recently announced plans for its upcoming phase III clinical trial. This trial will investigate its lead candidate lanifibranor as…

Continue Reading Inventiva Introduces Design for its Phase III Nonalcoholic Steatohepatitis Trial
Six-Part CME/CE Series Announced by The Cardiometabolic Health Congress
source: pixabay.com

Six-Part CME/CE Series Announced by The Cardiometabolic Health Congress

by Lauren Taylor from In The Cloud Copy The Cardiometabolic Health Congress announced that they would be holding a virtual event due to the COVID pandemic that would cover various…

Continue Reading Six-Part CME/CE Series Announced by The Cardiometabolic Health Congress
HemoShear & Takeda Partnership Identifies New Drug Target for NASH
source: pixabay.com

HemoShear & Takeda Partnership Identifies New Drug Target for NASH

In a recent press release, biotechnology company HemoShear Therapeutics ("HemoShear") shared that the company, in collaboration with Takeda Pharmaceutical Company Ltd. ("Takeda") identified a novel therapeutic target for nonalcoholic steatohepatitis…

Continue Reading HemoShear & Takeda Partnership Identifies New Drug Target for NASH

Axcella Presents its Investigational Products to Treat Liver Diseases and Type 2 Diabetes

Axcella is a biotechnology company that has developed a new system of treating complex diseases. Its lead candidates are products that treat two liver diseases, as well as NASH, which…

Continue Reading Axcella Presents its Investigational Products to Treat Liver Diseases and Type 2 Diabetes
VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat
source: pixabay.com

VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat

In November 2020, Viking Therapeutics ("Viking") shared insight into their metabolic disease program. According to Greg Zante, the Senior VP (SVP) of Finance for Viking, the company's treatment VK2809, licensed…

Continue Reading VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat
OCA Treatment Shows Fibrosis Improvement in NASH
https://pixabay.com/en/doctor-hospital-bed-delivery-labor-840127/

OCA Treatment Shows Fibrosis Improvement in NASH

  From November 13-16, researchers, doctors, and others participated in the American Association for the Study of Liver Diseases (AASLD)'s Annual Meeting, or The Liver Meeting Digital Experience. During the…

Continue Reading OCA Treatment Shows Fibrosis Improvement in NASH
Study Evaluates the Cost-Effectiveness of NASH and NAFLD Screening
source: pixabay.com

Study Evaluates the Cost-Effectiveness of NASH and NAFLD Screening

by Lauren Taylor from In The Cloud Copy Nonalcoholic fatty liver disease, or NAFLD, and nonalcoholic steatohepatitis, or NASH, are two conditions affecting the liver that plague millions of Americans…

Continue Reading Study Evaluates the Cost-Effectiveness of NASH and NAFLD Screening

Owlstone Medical Announces Successful Study Using Breath Biopsy to Measure Liver Function

Owlstone Medical recently announced the success of its patient study demonstrating its Breath Biopsy®, using limonene as a biomarker in measuring liver function. The study demonstrated how exhaled limonene, a…

Continue Reading Owlstone Medical Announces Successful Study Using Breath Biopsy to Measure Liver Function
The TARGET-NASH Study Finds Prior Opioid Use Prevalent in NAFLD Patients
source: pixabay.com

The TARGET-NASH Study Finds Prior Opioid Use Prevalent in NAFLD Patients

Target RWE, an innovative health evidence solutions company based in Durham, North Carolina recently announced its current data from the study of nonalcoholic steatohepatitis (NASH) via PRNewswire. The study, entitled…

Continue Reading The TARGET-NASH Study Finds Prior Opioid Use Prevalent in NAFLD Patients
More Research Needed to Help Postmenopausal Females at Risk for Nonalcoholic Fatty Liver Disease
source: pixabay.com

More Research Needed to Help Postmenopausal Females at Risk for Nonalcoholic Fatty Liver Disease

by Natalie Homan from In The Cloud Copy A review article published in Endocrinology in August of this year highlights the fact that a female's risk of developing nonalcoholic fatty…

Continue Reading More Research Needed to Help Postmenopausal Females at Risk for Nonalcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease: Study of Children Receiving Standard of Care Lifestyle Advice

by Danielle Bradshaw from In The Cloud Copy It’s possible for fat to end up stored inside of the liver due to either obesity, diabetes, certain medications, or high cholesterol.…

Continue Reading Non-alcoholic Fatty Liver Disease: Study of Children Receiving Standard of Care Lifestyle Advice
Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment
Source: Pixabay

Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment

Alnylam Pharmaceuticals has submitted their clinical trial authorization (CTA) application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for their RNAi therapy, ALN-HSD, a treatment for nonalcoholic steatohepatitis (NASH).…

Continue Reading Alnylam Submits a Clinical Trial Authorization Application for Their NASH Treatment
Data Supports Tesamorelin as Effective for HIV-Associated NASH
Arcaion / Pixabay

Data Supports Tesamorelin as Effective for HIV-Associated NASH

  Biopharmaceutical company Theratechnologies Inc. recently announced that its therapy candidate tesamorelin is effective in the treatment of HIV-associated nonalcoholic steatohepatitis (NASH). According to new data, published in JCI Insight, tesamorelin…

Continue Reading Data Supports Tesamorelin as Effective for HIV-Associated NASH
MRFF Funding Promotes Treatment Development for Patients with Rare Diseases
https://pixabay.com/en/money-piggy-bank-coins-finance-2180338/

MRFF Funding Promotes Treatment Development for Patients with Rare Diseases

  When it comes to researching and finding treatments for rare diseases, funding plays a crucial role. Recently, the Medical Research Future Fund (MRFF) Stem Cell Therapies Mission presented Monash…

Continue Reading MRFF Funding Promotes Treatment Development for Patients with Rare Diseases
NAFLD and NASH Predicted to Be a Growing Health Emergency
https://pixabay.com/en/doctor-hospital-bed-delivery-labor-840127/

NAFLD and NASH Predicted to Be a Growing Health Emergency

  In a Business Wire press release, the Canadian NASH Network (CanNASH) shared the results of a recent study predicting a severe increase in cases of nonalcoholic fatty liver disease…

Continue Reading NAFLD and NASH Predicted to Be a Growing Health Emergency
Podcast Series Released to Increase Awareness and Education for Nonalcoholic Steatohepatitis
source: pixabay.com

Podcast Series Released to Increase Awareness and Education for Nonalcoholic Steatohepatitis

International Nonalcoholic Steatohepatitis (NASH) Day takes place on June 12th every year. This year, a 4 part podcast series was released by NASHNET as part of the continued effort to spread…

Continue Reading Podcast Series Released to Increase Awareness and Education for Nonalcoholic Steatohepatitis
A New Phase 2 Trial Begins for Experimental Nonalcoholic Steatohepatitis Treatment
source: pixabay.com

A New Phase 2 Trial Begins for Experimental Nonalcoholic Steatohepatitis Treatment

According to a story from globenewswire.com, the biotechnology company CytoDyn Inc. has recently announced the initiation of a phase 2 clinical trial. This clinical trial will be testing the company's…

Continue Reading A New Phase 2 Trial Begins for Experimental Nonalcoholic Steatohepatitis Treatment
International Nonalcoholic Steatohepatitis (NASH) Day Sparks New Collaboration for Research
source: pixabay.com

International Nonalcoholic Steatohepatitis (NASH) Day Sparks New Collaboration for Research

International NASH Day, or IND, began in 2018 to raise awareness of nonalcoholic steatohepatitis (NASH). This is the most advanced form of fatty liver disease. It is a progressive condition…

Continue Reading International Nonalcoholic Steatohepatitis (NASH) Day Sparks New Collaboration for Research